PROGNOSTIC MARKERS IN PATIENTS WITH THYMUS-INDEPENDENT AND THYMUS-DEPENDENT MYASTHENIA GRAVIS

Objective. To assess the presence of specific markers in patients with thymus-independent and thymus-dependent myasthenia gravis for choosing treatment tactics. Methods. The was assessed 138 (M - without thymus changes) (MH hyperplasia, MT thymoma). method ELISA (the content antibodies to subunits 1 7 nAChR blood serum, subunit thymocyte mitochondria, a detectablelevel antinuclear antibody(ANA), immunofluorescence (ANA glow) flow cytometry (expression CD14+CD11c+and CD14 + HLA-DR +) has been used. Results. relationship between clinical phenotypes variants HLA diplotypes revealed: young (M), high heterogeneity genotypic (DR1, DR2, DR3, DR5, DR7) detected. Patients (MT) had only DR2 DR7 diplo- haplotypes. haplotypes some progressive (M) led development thymoma elderly people. pathogenic role also belongs infection (СMV, EBV, HBV, HCV, HSV-1, HSV-2, HHV-6, mycoplasma) food intolerance (IgE IgG4) progression gravis. A four-fold prevalence α7 nicotinic acetylcholine receptors on mitochondria as an additional targets autoimmune aggression determined. Specific centromere chromosome proteins were visualized people thymoma. Conclusion. prognosis remission can be made using genomic certain haplotypes) molecular proteins, expression CD20+, CD14+CD11c+, CD14+HLA-DR+) biomarkers, that used choice What this paper adds change complex biomarkers firstly studied tactics In haplotypes, increasing CD14+CD11c+ CD14+HLADR+ gravis, analogically thymoma, perform thymectomy is dangerous. potentialrisksof procedure.